SPAARK研究:脂质体布比卡因用于膝关节置换术围关节麻醉的患者盲随机对照优效性试验方案
共同主要结局为术后72小时恢复质量40量表评分和术后前3天每日累积疼痛视觉模拟评分。
要点
- 脂质体布比卡因可能延长术后镇痛时间至72小时。
- 研究同时评估恢复质量、累积疼痛、阿片消耗及成本效用。
- 当前局部麻醉切口浸润的主要局限是作用持续时间短。
核心结论
- 脂质体布比卡因在膝关节置换术中的临床与成本效果尚待本研究验证。
研究设计与样本
- 患者盲、多中心、活性对照、优效性、两组平行随机对照试验。
- 随机分为脂质体布比卡因联合盐酸布比卡因组或单用盐酸布比卡因组。
主要发现
- 原文未报告研究结果。
关键数值与推荐
- 共同主要结局为术后72小时恢复质量40量表评分和术后前3天每日累积疼痛视觉模拟评分(0-10分)。
- 次要结局包括累积阿片消耗、出院适合度、牛津膝关节评分、美国膝关节协会评分、EuroQol五维度工具及并发症。
- 计划进行成本效用分析。
临床怎么用
- 若证实优效,脂质体布比卡因可作为膝关节置换术后多模式镇痛的选择。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Optimising the management of peri-operative pain and recovery following knee replacement has been identified as a patient priority. Current pain relief strategies use opiate-based analgesia; however, up to 50% of patients experience significant side effects. Local anaesthetic incisional infiltration is one alternative. The length of the duration of action is a major limiting factor of current local anaesthetic techniques. Liposomal bupivacaine has been reported to be effective for up to 72 h. This randomised controlled trial will evaluate the clinical and cost effectiveness of liposomal bupivacaine. METHODS: SPAARK is a patient-blinded, multi-centre, active comparator, superiority, two-arm, parallel-group randomised controlled trial. Five hundred patients undergoing knee replacement will be recruited and randomised to liposomal bupivacaine plus bupivacaine hydrochloride or bupivacaine hydrochloride alone. The co-primary outcomes are the Quality of Recovery 40 measured at 72 h post-surgery and also cumulative pain measured daily using a 0-10 visual analogue scale for the first 3 days following surgery. Secondary outcomes include cumulative opioid consumption, fitness for discharge, functional outcomes assessed using the Oxford Knee Score and American Knee Society Score, the EuroQol five dimensions instrument and complications. A cost utility analysis is also planned. DISCUSSION: The clinical effectiveness and cost effectiveness of liposomal bupivacaine have yet to be evaluated in the National Health Service, making this trial appropriate and timely. TRIAL REGISTRATION: ISRCTN registry, ISRCTN54191675. Registered on 14 November 2017.
引用
- Knight R, Poulton L, Strickland LH, et al. Study of Peri-Articular Anaesthetic for Replacement of the Knee (SPAARK): study protocol for a patient-blinded, randomised controlled superiority trial of liposomal bupivacaine. Trials. 2019. PMID: 31842977. doi:10.1186/s13063-019-3826-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。